Skip to Content

Publications Search - Abstract View

Title: Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.
Authors: Trabert B,  Ness RB,  Lo-Ciganic WH,  Murphy MA,  Goode EL,  Poole EM,  Brinton LA,  Webb PM,  Nagle CM,  Jordan SJ,  Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer),  Risch HA,  Rossing MA,  Doherty JA,  Goodman MT,  Lurie G,  Kjær SK,  Hogdall E,  Jensen A,  Cramer DW,  Terry KL,  Vitonis A,  Bandera EV,  Olson S,  King MG,  Chandran U,  Anton-Culver H,  Ziogas A,  Menon U,  Gayther SA,  Ramus SJ,  Gentry-Maharaj A,  Wu AH,  Pearce CL,  Pike MC,  Berchuck A,  Schildkraut JM,  Wentzensen N,  Ovarian Cancer Association Consortium,  Bowtell D,  Chenevix-Trench G,  deFazio A,  Gertig D,  Green A,  Webb P,  Green A,  Parsons P,  Hayward N,  Webb P,  Whiteman D
Journal: J Natl Cancer Inst
Date: 2014 Feb
Branches: HREB
PubMed ID: 24503200
PMC ID: PMC3924755
Abstract: BACKGROUND: Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive. METHODS: We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided. RESULTS: Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95% CI = 0.64 to 0.91). CONCLUSIONS: Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.